Week Ending April 11, 2022

MD Anderson research highlights: AACR 2022 Special Edition
“Presentations on improving immunotherapy responses, understanding lung cancer development and metastasis, targeting mutant KRAS and early trial results”

CT woman advocates for cancer research after her own battle with lung cancer
“Over the course of a couple of years, Megan Naughton didn’t feel well.”

Simple changes in care reduced heart exposure during lung cancer radiation treatment
“By raising awareness about the correlation between increased radiation exposure and cardiac events, average doses were reduced without minimizing cancer treatment.”

Patient explains how hospital’s push to screen for lung cancer gave her a ‘second chance’
EDGEWOOD, Ky. —”Compared to other states, Kentucky ranks at or near the top of every list when it comes to lung cancer diagnoses and deaths. Fortunately, the state is also near the top of the list in early testing for lung cancer.”

Three Year Follow-Up Data from Phase 3 CROWN Trial of Pfizer’s LORBRENA® (lorlatinib) Confirm Prolonged Progression-Free Survival in First-Line ALK-Positive Advanced Lung Cancer
NEW YORK, NY, April 8, 2022 – “Pfizer Inc. announced updated results from the Phase 3 CROWN trial, which evaluated LORBRENA® (lorlatinib, available in Europe under the brand name LORVIQUA) versus XALKORI® (crizotinib) in people with previously untreated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC).”

Survival Benefit of Pembrolizumab Sustained After 4 Years in Chinese Patients With NSCLC
“In the phase 3 China extension KEYNOTE-042 clinical trial (NCT03850444), treatment with pembrolizumab (Keytruda) monotherapy in the frontline setting showed overall survival (OS) benefit and durable tumor response vs standard-of-care platinum-based chemotherapy in Chinese patients with untreated PD-L1–positive, advanced or metastatic non–small cell lung cancer (NSCLC) without sensitizing EGFR or ALK mutations, according to a presentation given during the AACR Annual Meeting 2022.1

COPD Associated With Complications, Longer LOS After Lung Cancer Surgery
“A retrospective study found that chronic obstructive pulmonary disease (COPD) was associated with postoperative pulmonary complications and longer length of stay (LOS) following lung cancer resection.”

FDA Grants Orphan Drug Status to Serplulimab for Small Cell Lung Cancer
“The FDA has granted orphan drug designation to serplulimab (HLX10) for the treatment of patients with small cell lung cancer (SCLC), according to a press release issued by its developer, Shanghai Henlius Biotech, Inc.1

Furmonertinib Deemed Potential First-Line Option for EGFR-Mutated NSCLC
“First-line furmonertinib can prolong progression-free survival (PFS), when compared with gefitinib, in patients with EGFR-mutated, advanced non-small cell lung cancer (NSCLC), according to results from the phase 3 FURLONG trial.”

Adding Camrelizumab to Chemo Improves OS in Advanced Squamous NSCLC
“Adding camrelizumab to chemotherapy provides an overall survival (OS) benefit in patients with advanced squamous non-small cell lung cancer (NSCLC), according to updated results from the phase 3 CameL-sq trial.1

Acclaim-2 Explores Ozeplasmid Plus Pembrolizumab in Late-Stage NSCLC
“The phase 1/2 Acclaim-2 trial (NCT05062980) evaluating ozeplasmid (Reqorsa) in combination with pembrolizumab (Keytruda) in patients with late-stage non-small cell lung cancer (NSCLC) whose disease progressed after treatment with pembrolizumab has announced the opening of enrollment, according to a press release by Genprex, Inc.1

Overview of New Drugs in Non-small Cell Lung Cancer, Implications for the Treatment Landscape
“Melissa Johnson, MD, program director of Lung Cancer Research at the Sarah Cannon Research Institute, discusses her presentation at the Community Oncology Alliance 2022 conference on new drugs in the non-small cell lung cancer space.”

Young Mother Who Survived Lung Cancer Wants All Californians to Have Access to Life-Saving Care
“When Tabitha Paccione started having coughing fits and severe fatigue in 2015, doctors couldn’t figure out why.”

Dr Melissa Johnson Underscores the Need for Lung Cancer Screening Guidance for Never-Smokers
“Melissa Johnson, MD, program director of Lung Cancer Research at Sarah Cannon, discusses the need for increased lung cancer screening among patients who have no tobacco use history.”